Furthermore, based on the key roles of CCR5 on both melanoma cells and MDSCs, blocking CCR5 may help to: (a) limit the metastatic potential of melanoma cells, (b) reduce the number of immunosuppressive cells within the TME, and (c) enhance the infiltration of CTLs into tumours. Here, CCR5 is linked to neoplasm.